OUTLOOK THERAPEUTICS INC (OTLK) Stock Fundamental Analysis

NASDAQ:OTLK • US69012T3059

0.4144 USD
-0.02 (-4.65%)
Last: Feb 20, 2026, 03:03 PM
Fundamental Rating

1

Overall OTLK gets a fundamental rating of 1 out of 10. We evaluated OTLK against 521 industry peers in the Biotechnology industry. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative. OTLK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OTLK has reported negative net income.
  • In the past year OTLK has reported a negative cash flow from operations.
  • In the past 5 years OTLK always reported negative net income.
  • OTLK had a negative operating cash flow in each of the past 5 years.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • OTLK has a worse Return On Assets (-335.90%) than 91.94% of its industry peers.
Industry RankSector Rank
ROA -335.9%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K -1.5K

1.3 Margins

  • Looking at the Gross Margin, with a value of 3.80%, OTLK is in the better half of the industry, outperforming 72.17% of the companies in the same industry.
  • OTLK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

0

2. Health

2.1 Basic Checks

  • OTLK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for OTLK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • OTLK has an Altman-Z score of -58.91. This is a bad value and indicates that OTLK is not financially healthy and even has some risk of bankruptcy.
  • OTLK's Altman-Z score of -58.91 is on the low side compared to the rest of the industry. OTLK is outperformed by 90.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -58.91
ROIC/WACCN/A
WACC8.22%
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

2.3 Liquidity

  • OTLK has a Current Ratio of 0.38. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of OTLK (0.38) is worse than 91.36% of its industry peers.
  • A Quick Ratio of 0.31 indicates that OTLK may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.31, OTLK is not doing good in the industry: 91.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.31
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

3

3. Growth

3.1 Past

  • OTLK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.64%, which is quite impressive.
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • OTLK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.99% yearly.
  • OTLK is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.18% yearly.
EPS Next Y-49.76%
EPS Next 2Y-4.15%
EPS Next 3Y17.24%
EPS Next 5Y10.99%
Revenue Next Year214.53%
Revenue Next 2Y168.9%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%

3.3 Evolution

OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 2033 10M 20M 30M 40M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 -100 -200 -300

0

4. Valuation

4.1 Price/Earnings Ratio

  • OTLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year OTLK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OTLK's earnings are expected to grow with 17.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.15%
EPS Next 3Y17.24%

0

5. Dividend

5.1 Amount

  • No dividends for OTLK!.
Industry RankSector Rank
Dividend Yield 0%

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (2/20/2026, 3:03:47 PM)

0.4144

-0.02 (-4.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-19
Earnings (Next)02-23
Inst Owners6.34%
Inst Owner Change23.76%
Ins Owners0.06%
Ins Owner Change0%
Market Cap30.46M
Revenue(TTM)1.51M
Net Income(TTM)-62.42M
Analysts78
Price Target5.48 (1222.39%)
Short Float %7.6%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.31%
Min EPS beat(2)-37.09%
Max EPS beat(2)26.47%
EPS beat(4)3
Avg EPS beat(4)53.72%
Min EPS beat(4)-37.09%
Max EPS beat(4)191.08%
EPS beat(8)6
Avg EPS beat(8)45.68%
EPS beat(12)8
Avg EPS beat(12)27.91%
EPS beat(16)9
Avg EPS beat(16)16.62%
Revenue beat(2)0
Avg Revenue beat(2)-56.4%
Min Revenue beat(2)-101.54%
Max Revenue beat(2)-11.26%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.42%
PT rev (3m)-42.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100%
EPS NY rev (1m)36.43%
EPS NY rev (3m)36.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.22%
Revenue NY rev (1m)-9.14%
Revenue NY rev (3m)-29.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0.02
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -335.9%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.8%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.31
Altman-Z -58.91
F-Score4
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
EPS Next Y-49.76%
EPS Next 2Y-4.15%
EPS Next 3Y17.24%
EPS Next 5Y10.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year214.53%
Revenue Next 2Y168.9%
Revenue Next 3Y50.35%
Revenue Next 5Y35.18%
EBIT growth 1Y7.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.66%
OCF growth 3YN/A
OCF growth 5YN/A

OUTLOOK THERAPEUTICS INC / OTLK FAQ

What is the ChartMill fundamental rating of OUTLOOK THERAPEUTICS INC (OTLK) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OTLK.


Can you provide the valuation status for OUTLOOK THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OUTLOOK THERAPEUTICS INC (OTLK). This can be considered as Overvalued.


How profitable is OUTLOOK THERAPEUTICS INC (OTLK) stock?

OUTLOOK THERAPEUTICS INC (OTLK) has a profitability rating of 1 / 10.


Can you provide the financial health for OTLK stock?

The financial health rating of OUTLOOK THERAPEUTICS INC (OTLK) is 0 / 10.